Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Abbreviated MgSO4 Therapy in Post-Partum Preeclampsia

This study has been completed.
Information provided by:
Case Western Reserve University Identifier:
First received: June 23, 2006
Last updated: NA
Last verified: August 2005
History: No changes posted
Magnesium sulfate is used for seizure prophylaxis in pregnancies complicated by preeclampsia. There is debate as to how long to continue this therapy after delivery of the pregnancy. Different schemes have been offered to shorten the exposure to magnesium sulfate after delivery, with little data. We seek to investigate the effect of shortened magnesium sulfate therapy on the post-partum recovery phase of mild preeclampsia. Our hypothesis was that shortened therapy (12 hours versus the traditional 24 hours post-partum) has no effect on disease course, and will result in significantly shorter exposure to magnesium sulfate.

Condition Intervention
Drug: abbreviation of magnesium sulfate therapy (12 hours versus the traditional 24 hours after delivery)

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Abbreviated Post-Partum Magnesium Sulfate Seizure Prophylaxis in Preeclampsia: A Comparison of 12 and 24 Hour Regimens

Resource links provided by NLM:

Further study details as provided by Case Western Reserve University:

Primary Outcome Measures:
  • Time of magnesium sulfate therapy (minutes)
  • Blood pressure
  • Maternal symptoms (headaches, blurred vision, chest pain, shortness of breath)

Estimated Enrollment: 200
Study Start Date: January 2001
Estimated Study Completion Date: August 2004
Detailed Description:

The study has been completed at this time.

Consenting women with suspected mild preeclampsia (new onset/exacerbated hypertension with proteinuria) were randomly assigned 12 (12-hour) or 24-hours (24-hour) of postpartum MgSO4. Treatment was continued beyond the initially assigned time period for new findings of severe preeclampsia. Clinical and laboratory data were collected. Analysis was by intent to treat, utilizing Fisher’s exact, chi-square, and Student’s t-tests where appropriate


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Women with suspected mild preeclampsia diagnosed antepartum, intrapartum, or post-partum were eligible for inclusion after delivery at term (≥ 34 weeks’ gestational age).

Exclusion Criteria:

  • Inability to give informed consent, preterm delivery, severe preeclampsia
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00344058

United States, Ohio
MetroHealth Medical Center, Labor and Delivery
Cleveland, Ohio, United States, 44109
Sponsors and Collaborators
Case Western Reserve University
Principal Investigator: Hugh M Ehrenberg, MD MetroHealth Medical Center at Case Western Reserve School of Medicine
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00344058     History of Changes
Other Study ID Numbers: IRB 01001-OBG-01
Study First Received: June 23, 2006
Last Updated: June 23, 2006

Keywords provided by Case Western Reserve University:

Additional relevant MeSH terms:
Hypertension, Pregnancy-Induced
Pregnancy Complications
Magnesium Sulfate
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Central Nervous System Depressants
Anti-Arrhythmia Agents
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Tocolytic Agents
Reproductive Control Agents processed this record on April 28, 2017